InvestorsHub Logo
Followers 61
Posts 9563
Boards Moderated 0
Alias Born 03/29/2015

Re: voloda69 post# 524155

Sunday, 10/23/2022 4:45:08 PM

Sunday, October 23, 2022 4:45:08 PM

Post# of 698815
Good find! Now NWBO could have an intern put the link in the “NWBO in the news” section of their website which any company could maintain without it being called ‘hyping.’

Oh wait…can’t do even that.

The article is poorly written and makes it look almost like NICE said DCVax-L was not effective:

The couple got married earlier this month and Owain is now undergoing intensive chemotherapy and radiotherapy but has been told by his doctor that two kinds of treatment could extend his life - one called DCVax and one called Optune.
'Insufficient evidence of effectiveness'
DCVax, a type of immunotherapy, uses a vaccine which utilises the body's immune cells to target the cancer.
It is currently in the third phase of clinical trials but initial results suggest it could help patients like Owain.
Optune is a device that looks like a skull cap which creates electrical fields to disrupt tumour cell division.
In 2018, the body which advises the NHS on treatments, NICE, said there was "insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to make the technology cost effective".

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News